Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2018 (2018), Article ID 9010353, 6 pages
https://doi.org/10.1155/2018/9010353
Research Article

Mutational Profiling of Non-Small-Cell Lung Cancer Resistant to Osimertinib Using Next-Generation Sequencing in Chinese Patients

1Department of Radiotherapy, Qingdao Cancer Hospital, Qingdao 266042, China
2Department of Oncology, The Affiliated Hospital of Qingdao University, Qingdao 266002, China
3Department of Oncology, The Affiliated Qingdao Central Hospital of Qingdao University, Qingdao 266042, China
4Oncology Genemic, Geneplus Beijing, Beijing 100010, China

Correspondence should be addressed to Youxin Ji; moc.liamg@ij987654321

Received 19 December 2017; Revised 23 January 2018; Accepted 6 February 2018; Published 11 March 2018

Academic Editor: Valli De Re

Copyright © 2018 Keke Nie et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Suda, R. Onozato, Y. Yatabe, and T. Mitsudomi, “EGFR T790M mutation: A double role in lung cancer cell survival?” Journal of Thoracic Oncology, vol. 4, no. 1, pp. 1–4, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. Y. Yin and J. Li, “Osimertinib in EGFR T790M - Positive lung cancer,” The New England Journal of Medicine, vol. 376, no. 20, p. 1993, 2017. View at Publisher · View at Google Scholar · View at Scopus
  3. F. H. Knebel, F. Bettoni, A. K. Shimada et al., “Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC,” Lung Cancer, vol. 108, pp. 238–241, 2017. View at Publisher · View at Google Scholar · View at Scopus
  4. I. Vanni, S. Coco, A. Truini et al., “Next-generation sequencing workflow for NSCLC critical samples using a targeted sequencing approach by ion torrent PGM platform,” International Journal of Molecular Sciences, vol. 16, no. 12, pp. 28765–28782, 2015. View at Publisher · View at Google Scholar
  5. V. H. Veldore, S. Patil, C. Satheesh et al., “Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: an effort to explore new drug targets,” Indian Journal of Cancer, vol. 52, no. 2, pp. 243–248, 2015. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Oztan, S. Fischer, A. B. Schrock et al., “Emergence of EGFR G724S mutation in EGFR-mutant lung adenocarcinoma post progression on osimertinib,” Lung Cancer, vol. 111, pp. 84–87, 2017. View at Publisher · View at Google Scholar · View at Scopus
  7. Z. Tang, M. Su, X. Guo et al., “Increased expression of IRE1α associates with the resistant mechanism of osimertinib (AZD9291)-resistant non-small cell lung cancer HCC827/OSIR cells,” Anti-Cancer Agents in Medicinal Chemistry, vol. 17, 2017. View at Publisher · View at Google Scholar
  8. N. Hidaka, E. Iwama, N. Kubo et al., “Most T790M mutations are present on the same EGFR allele as activating mutations in patients with non–small cell lung cancer,” Lung Cancer, vol. 108, pp. 75–82, 2017. View at Publisher · View at Google Scholar · View at Scopus
  9. L. H. Schwartz, S. Litière, E. De Vries et al., “RECIST 1.1 - Update and clarification: From the RECIST committee,” European Journal of Cancer, vol. 62, pp. 132–137, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. J.-Q. Zhu, W.-Z. Zhong, G.-C. Zhang et al., “Better survival with EGFR exon 19 than exon 21 mutations in gefitinib-treated non-small cell lung cancer patients is due to differential inhibition of downstream signals,” Cancer Letters, vol. 265, no. 2, pp. 307–317, 2008. View at Publisher · View at Google Scholar · View at Scopus
  11. C. Zhou, Y.-L. Wu, G. Chen et al., “Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study,” The Lancet Oncology, vol. 12, no. 8, pp. 735–742, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. T. S. Mok, Y.-L. Wu, S. Thongprasert et al., “Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma,” The New England Journal of Medicine, vol. 361, no. 10, pp. 947–957, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. P. A. Jänne, J. Chih-Hsin Yang, D.-W. Kim et al., “AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer,” The New England Journal of Medicine, vol. 372, no. 18, pp. 1689–1699, 2015. View at Publisher · View at Google Scholar · View at Scopus
  14. T. Jiang and C. Zhou, “Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients with EGFR inhibitor-resistant non-small cell lung cancer,” Translational Lung Cancer Research, vol. 3, no. 6, pp. 370–372, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. Y. Jia, C.-H. Yun, E. Park et al., “Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors,” Nature, vol. 534, no. 7605, pp. 129–132, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. R. Menon, J. Müller, P. Schneider et al., “A Novel EGFRC797 Variant Detected in a Pleural Biopsy Specimen from an Osimertinib-Treated Patient Using a Comprehensive Hybrid Capture-Based Next-Generation Sequencing Assay,” Journal of Thoracic Oncology, vol. 11, no. 9, pp. e105–e107, 2016. View at Publisher · View at Google Scholar · View at Scopus
  17. K. S. Thress, C. P. Paweletz, E. Felip et al., “Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M,” Nature Medicine, vol. 21, no. 6, pp. 560–562, 2015. View at Publisher · View at Google Scholar · View at Scopus
  18. Z. Wang, J.-J. Yang, J. Huang et al., “Lung Adenocarcinoma Harboring EGFR T790M and In Trans C797S Responds to Combination Therapy of First- and Third-Generation EGFR TKIs and Shifts Allelic Configuration at Resistance,” Journal of Thoracic Oncology, 2017. View at Publisher · View at Google Scholar · View at Scopus
  19. D. Ercan, H. G. Choi, C.-H. Yun et al., “EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors,” Clinical Cancer Research, vol. 21, no. 17, pp. 3913–3923, 2015. View at Publisher · View at Google Scholar · View at Scopus
  20. J. A. Engelman, K. Zejnullahu, T. Mitsudomi et al., “MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling,” Science, vol. 316, no. 5827, pp. 1039–1043, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. Z. Piotrowska, M. J. Niederst, C. A. Karlovich et al., “Heterogeneity Underlies the Emergence of EGFRT790 Wild-Type Clones Following Treatment of T790M-Positive Cancers with a Third-Generation EGFR Inhibitor,” Cancer Discovery, vol. 5, no. 7, pp. 713–722, 2015. View at Google Scholar
  22. D. Planchard, Y. Loriot, F. André et al., “EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients,” Annals of Oncology, vol. 26, no. 10, Article ID mdv319, pp. 2073–2078, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. S. S. Ramalingam, J. C. Yang, C. K. Lee et al., “Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer,” Journal of Clinical Oncology, Article ID JCO2017747576, 2017. View at Google Scholar
  24. R. Minari, P. Bordi, M. Del Re et al., “Primary resistance to osimertinib due to SCLC transformation: Issue of T790M determination on liquid re-biopsy,” Lung Cancer, vol. 115, pp. 21–27, 2018. View at Publisher · View at Google Scholar